Aplagon secures EUR 7 million in funding led by Fåhraeus Startup and Growth and EIC Fund to advance its innovative therapeutic APAC for thrombo-inflammatory diseases.

Information on the Target

Aplagon Oy is a clinical-stage biopharmaceutical company based in Helsinki, Finland, focused on developing APAC, an innovative therapeutic for thrombo-inflammatory diseases. APAC, a heparin proteoglycan mimetic, exhibits both antiplatelet and anticoagulant effects, targeting arterial injury sites to provide sustained antithrombotic and anti-inflammatory actions. With a successful EUR 7 million funding round led by Fåhraeus Startup and Growth AB (FSG) and the European Innovation Council (EIC) Fund, the company plans to initiate a Phase 2a clinical trial for peripheral arterial occlusive disease/chronic limb-threatening ischemia (PAOD/CLTI) in Finland.

Aplagon has multiple clinical trials underway, including a Phase I study on arteriovenous fistula maturation failure and a PET-imaging trial using 89 zirconium-labeled APAC. Initial safety assessments have shown encouraging results, with over 40 participants treated without adverse events.

Industry Overview in Finland

Finland's biopharmaceutical sector has been on an upward trajectory, driven by a robust research foundation and increasing investments in healthcare technologies. The collaboration between academic institutions and industry players enhances inno